Taking a plunge into the healthcare sector when it’s fighting with a huge image problem requires courage. Moreover, when the investment product targets the biotech sector – which recently witnessed a big sell-off amid a raging drug-pricing controversy, questions are bound to be raised about the timing.
But for Brad Loncar, the Kansas based former budget manager in the international affairs division at the US Department of Treasury and a full-time biotech investor for over eight years, the time was ripe to give investors access to a very hot slice of the biotech sector – cancer immunotherapy.
For the uninitiated, immunotherapy involves manipulating the human body’s immune system to target and kill the cancerous cells, malignant or otherwise. Since the body’s own defence system is activated against carcinogenic cells, immunotherapy is far more potent and safe than traditional surgery and chemotherapy. Indeed, immunotherapy products can bring revolutionary breakthroughs and bring a paradigm shift in cancer treatment.





